Skip to main content

Table 1 Participants’ demographics and clinical characteristics

From: Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture

  All Anti-CCP+
(≥7 U/ml)
Anti-CCP−
(<7 U/ml)
p Value
No. of subjects (%)a 521 (100) 359 (68.9) 162 (31.1)  
Female sex, n (%)a 447 (85.8) 306 (85.24) 141 (87.04) 0.5858
Menopause, n (%)a 359 (80.3) 252 (82.4) 107 (75.9) 0.1101
Menopause, yearsb 50.0 (2.0) 50.0 (2.0) 50.0 (2.0) 0.6553
Age, yearsb 59.0 (14.0) 60.0 (14.0) 58.0 (14.0) 0.1700
BMI,b kg/m2 23.1 (5.0) 23.0 (5.1) 23.1 (4.3) 0.7470
Symptom to diagnosis, yearsb 2.0 (6.0)
n = 508
2.0 (6.0)
n = 159
2.0 (6.0)
n = 349
0.4732
Disease duration, yearsb 11.0 (13.0)
n = 491
12.0 (13.0)
n = 335
10.5 (13.5)
n = 156
0.6656
Comorbidity, n (%)a 315 (60.5) 213 (59.3) 102 (63.0) 0.4326
Anti-CCP, U/ml, mean (SD)b 62.0 (294.9) 183.0 (283.0) 0.9 (1.1) <0.0001
RF+, n (%)a 347 (67.1)
n = 517
306 (86.2)
n = 355
41 (25.3)
n = 162
<0.0001
RF, IU/mlb 56.6 (189.4)
n = 517
129.0 (288.9)
n = 355
10.6 (6.8)
n = 162
<0.0001
ESR, mm/h b 17.0 (22.0) 19.0 (24.0) 13.5 (18.0) <0.0001
CRP, mg/L b 2.5 (7.7)
n = 519
3.2 (8.6)
n = 358
1.7 (5.6)
n = 161
0.0005
DAS28-ESRb 3.1 (1.7)
n = 519
3.2 (1.7)
n = 358
2.8 (1.4)
n = 161
0.0001
bDMARD, n (%)a 94 (18.0) 71 (19.8) 23 (14.2) 0.1253
Glucocorticoid users, n (%)a 452 (86.8) 317 (88.3) 135 (83.3) 0.1215
Alcohol ≥ 3 U/day, n (%)a 6 (1.2) 4 (1.1) 2 (1.2) 0.9051
Current smoker, n (%)a 35 (6.7) 30 (8.4) 5 (3.1) 0.0261
Fall in the previous year, n (%)a 97 (19.1)
n = 507
69 (19.8)
n = 348
28 (17.6)
n = 159
0.5559
Parent fractured hip, n (%)a 37 (7.1) 25 (7.0) 12 (7.6) 0.8552
BMD, g/cm2
 Spine (L1–L4)b 0.858 (0.209)
n = 501
0.850 (0.210)
n = 343
0.883 (0.187)
n = 158
0.0674
 Hip (total)c 0.780 ± 0.146
n = 497
0.774 ± 0.145
n = 342
0.794 ± 0.149
n = 155
0.1518
 FNb 0.620 (0.147)
n = 497
0.614 (0.144)
n = 342
0.643 (0.142)
n = 155
0.0196
Osteoporosis,d n (%)a 150 (29.47)
n = 509
111 (31.7)
n = 350
39 (24.5)
n = 159
0.0993
Previous fracture, n (%)a 97 (18.6) 67 (18.7) 30 (18.5) 0.9687
Current antiosteoporosis, n (%)a 104 (20.0) 27 (16. 7) 77 (21.5) 0.2062
Majorb,e 14.0 (17.2) 15.0 (18.9) 12.0 (15.3) 0.0461
Hipb,f 4.5 (8.5) 5.0 (9.2) 3.6 (8.2) 0.0118
  1. Abbreviations: BMI Body mass index, Anti-CCP Anticitrullinated protein antibodies, RF Rheumatoid factor, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, bDMARD Biologic disease-modifying antirheumatic drug, BMD Bone mineral density, FN Femoral neck
  2. a Absolute number (percent)
  3. b Median (IQR)
  4. c Mean ± SD
  5. d FN T-score less than or equal to −2.5
  6. e Ten-year probability of major fracture
  7. f Ten-year probability of hip fracture